Syndrome of inappropriate anti-diuretic hormone secretion secondary to carboplatin after docetaxel-carboplatin-trastuzumab combination for early stage HER-2 positive breast cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 3, 2012, Pages

  Turner, Natalie ^a,b   Stewart, Josephine ^a,b   Barnett, Frances ^a   White, Shane ^a,b  

^a NORTHERN HOSPITAL   (Australia)

^b AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; MAGNESIUM; POTASSIUM; SODIUM; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CHLORIDE BLOOD LEVEL; DRUG INDUCED DISEASE; FEMALE; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; LETHARGY; MAGNESIUM BLOOD LEVEL; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SERUM OSMOLALITY; SODIUM BLOOD LEVEL;

EID: 85027955729     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01526.x     Document Type: Article

References (14)

1. Ozols RF, Bundy BN, Greer BE etal. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-200.
2. Nogue-Aliguer M, Carles J, Arrivi A etal. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer 2003; 97: 2180-6.
3. Forastiere AA, Metch B, Schuller DE etal. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-51.
4. Schiller JH, Harrington D, Belani CP etal. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
5. Hotta K, Matsuo K, Ueoka H etal. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-9.
6. Slamon D, Eiermann W, Robert N etal. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at 29th Annual San Antonio Breast Cancer Symposium; 14-17 December 2006; San Antonio, TX. Abstract 52.
7. Abdelghani L, Modha K, Albaddawi E, Subramanian S. Sodium-wasting nephropathy caused by cisplatin in esophageal cancer. J Support Oncol 2008; 7: 305-6.
8. Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer 2007; 15: 1314-7.
9. Berger AK, Bellos F, Siegmund A, Eisenbach C, Lordick F. Symptomatic hyponatraemia caused by cyclophosphamide. Onkologie 2009; 32: 280-2.
10. Escuro RS, Adelstein DJ, Carter SG. Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine. Cleve Clin J Med 1992; 59: 642-4.
11. Fujioka S, Nakamura H, Miwa K etal. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following carboplatin-paclitaxel administration in a patient with lung cancer. Pharmazie 2011; 66: 729-30.
12. Yokoyama Y, Shigeto T, Fugagami M, Mizunuma H. Syndrome of inappropriate secretion of anti-diuretic hormone following carboplatin-paclitaxel administration in a patient with recurrent ovarian cancer. Eur J Gynaecol Oncol 2005; 26: 531-2.
13. Tscherning C, Rubie H, Chancholle A etal. Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer 1994; 73: 1761-3.
14. Kleta R, Wagner A, Jürgens H. Recurrence of SIADH after a high-dose regimen of thiotepa, carboplatin, and etoposide phosphate. Med Pediatr Oncol 1998; 31: 129.